NCT02886884View on ClinicalTrials.gov

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

August 26, 2019

Study Completion Date

September 3, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

20 million Allogeneic Mesenchymal Human Stem Cells

1 single intravenous infusion

DRUG

100 million Allogeneic Mesenchymal Human Stem Cells

1 single intravenous infusion

Trial Locations (1)

33136

University of Miami Miller School of Medicine, Miami

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Joshua M Hare

OTHER

NCT02886884 - Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects | Biotech Hunter | Biotech Hunter